(Q45411816)

English

Immune response in rhesus macaques after mixed modality immunisations with DNA, recombinant adenovirus and recombinant gp120 from human immunodeficiency virus type 1.

scientific article published in October 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Immune response in rhesus macaques after mixed modality immunisations with DNA, recombinant adenovirus and recombinant gp120 from human immunodeficiency virus type 1. (English)

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

1 reference

based on heuristic

inferred from title

object named as

Lasse Vinner

1

0 references

Anders Fomsgaard

object named as

Anders Fomsgaard

7

0 references

author name string

Dominic Therrien

2

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Edd Wee

3

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Inga Laursen

4

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Tomàs Hanke

5

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Sylvie L Corbet

6

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

publication date

1 October 2006

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Acta Pathologica et Microbiologica Scandinavica

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

114

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

690-699

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Immunogenicity in Mamu-A*01 rhesus macaques of a CCR5-tropic human immunodeficiency virus type 1 envelope from the primary isolate (Bx08) after synthetic DNA prime and recombinant adenovirus 5 boost

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_395.X

21 January 2018

HIV-1 DNA vaccines

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_395.X

21 January 2018

Poxvirus-based vaccine candidates for HIV: two decades of experience with special emphasis on canarypox vectors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_395.X

21 January 2018

MVA as a vector for vaccines against HIV-1.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_395.X

21 January 2018

Induction of mucosal immunity with a replication-defective adenoviral recombinant

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_395.X

21 January 2018

Boosting of SIV-specific immune responses in rhesus macaques by repeated administration of Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinants

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_395.X

21 January 2018

A call for replicating vector prime-protein boost strategies in HIV vaccine design

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_395.X

21 January 2018

Neutralizing antibody responses to HIV: role in protective immunity and challenges for vaccine design.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_395.X

21 January 2018

Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_395.X

21 January 2018

ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_395.X

21 January 2018

Potent, persistent induction and modulation of cellular immune responses in rhesus macaques primed with Ad5hr-simian immunodeficiency virus (SIV) env/rev, gag, and/or nef vaccines and boosted with SIV gp120.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_395.X

21 January 2018

Antigenic properties of recombinant envelope glycoproteins derived from T-cell-line-adapted isolates or primary human immunodeficiency virus isolates and their relationship to immunogenicity

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_395.X

21 January 2018

Immunogenicity of recombinant envelope glycoproteins derived from T-cell line-adapted isolates or primary HIV isolates: a comparative study using multivalent vaccine approaches

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_395.X

21 January 2018

Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_395.X

21 January 2018

Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_395.X

21 January 2018

Induction of neutralizing antibodies and gag-specific cellular immune responses to an R5 primary isolate of human immunodeficiency virus type 1 in rhesus macaques

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_395.X

21 January 2018

Construction, biological activity, and immunogenicity of synthetic envelope DNA vaccines based on a primary, CCR5-tropic, early HIV type 1 isolate (BX08) with human codons

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_395.X

21 January 2018

Replication-defective vector based on a chimpanzee adenovirus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_395.X

21 January 2018

HIV vaccines: brief review and discussion of future directions.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_395.X

21 January 2018

Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_395.X

21 January 2018

Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_395.X

21 January 2018

Human immunodeficiency virus type 1-specific immune responses in primates upon sequential immunization with adenoviral vaccine carriers of human and simian serotypes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_395.X

21 January 2018

Comparative Immunogenicity in Rhesus Monkeys of DNA Plasmid, Recombinant Vaccinia Virus, and Replication-Defective Adenovirus Vectors Expressing a Human Immunodeficiency Virus Type 1 gag Gene

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_395.X

21 January 2018

Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_395.X

21 January 2018

Prime-boost immunization schedules based on influenza virus and vaccinia virus vectors potentiate cellular immune responses against human immunodeficiency virus Env protein systemically and in the genitorectal draining lymph nodes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_395.X

21 January 2018

Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous Simian/human immunodeficiency virus infection in pigtailed macaques

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_395.X

21 January 2018

AIDS vaccines: back to 'plan A'.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_395.X

21 January 2018

Overcoming immunity to a viral vaccine by DNA priming before vector boosting

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_395.X

21 January 2018

ISCOMs and other saponin based adjuvants

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_395.X

21 January 2018

Identifiers

10.1111/J.1600-0463.2006.APM_395.X

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45411816&oldid=1247381535"